ClinicalTrials.gg
RecruitingNCT04477928PLEDGEUpdated Mar 2, 2026

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

An observational study in Type 1 Diabetes and Celiac Disease, sponsored by Sanford Health. Recruiting at 4 sites in United States. Open to participants aged 0 Minutes to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Sanford Health · Observational

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
33,000
Ages
0 Minutes to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
4th of 203
33,000 · median 63
Started
2020
with 70 others
Observational
203 of 1,458
34 open now
Primary completion
2031-03
later than 244 of 256 live
Registered
1,052nd of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 4th largest by planned enrollment of the 203 observational ones that give a count, is one of 71 that started in 2020, is one of 203 observational ones, reaches primary completion later than 244 of the 256 other live ones, and was the 1,052nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 0 Minutes to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

In partnership with Helmsley Charitable Trust, the Sanford PLEDGE Study is a large-scale, observational, feasibility study of general population screening for T1D and celiac autoantibodies. Screening is incorporated into routine health care visits within an integrated health system.

Read the detailed description

Most children with type 1 diabetes (T1D) do not have a family member with diabetes and often are not diagnosed until the child is very sick. Research suggests that screening and identifying children at risk for T1D autoantibodies can prevent serious illness at the time of diagnosis and improve long-term health outcomes.

The investigators will screen children, ages 0-5.99 or 9-16 years for blood markers related to T1D and celiac disease during routine healthcare delivery at birth, 1, 2 and 5 years, or once between 9 and 16 years of age. Children with confirmed autoantibodies will be offered participation in other monitoring or prevention trials (T1D), or referred to clinical care (celiac).

03

Conditions studied

  • Type 1 Diabetes
  • Celiac Disease

Keywords

  • Population screening
  • Type 1 Diabetes
  • Celiac Disease
  • Autoantibodies
  • Prevention
  • Diabetic Ketoacidosis (DKA)
  • Genetic Risk Score
  • Differential Gene Expression
  • Economic Modeling
  • Quality of Life
  • Feasibility
  • Pragmatic
  • T1D
04

Who can participate

Ages eligible
0 Minutes to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children born at and/or followed at Sanford Health System facilities:

  1. . 0-5 years of age;
  2. . 9-16 years of age;
  3. . Siblings of children known to have T1D-relevant antibodies, ages 6 to 17 years old.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborn Entry: Viable, term infants, defined as 36 weeks gestation by either dates or ultrasound who are born to pregnant women, 18 years or older, who are willing and able to provide (IC) prior to the onset of active labor. Who are born at a Sanford Health Hospital and plan to have routine well-child care at a Sanford Clinic
  • Pediatric Entry: Children less than 6 years of age who receive their routine care at a Sanford facility and whose parents are able to provide IC.
  • Adolescent Entry: Children, ages 9-16 years old, who receive their routine care at a Sanford facility and whose parents are able to provide IC.
  • Siblings of children known to have T1D-relevant antibodies; ages 6 to 17 years old who receive care at a Sanford clinic
  • Have an active MyChart account (with proxy access).

Exclusion criteria

Exclusion Criteria:

  • Subject is in the opinion of the investigator, unable to comply with the requirements of the study protocol.
  • Children known to have T1D
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
33,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study Group

    Children receiving routine care at a Sanford facility

    Diagnostic Test: Sera and whole blood sampling · Diagnostic Test: Differential Gene Expression (DGE)

Interventions

  • Diagnostic testSera and whole blood sampling

    * Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry. * 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies * 5 years old: T1D and celiac autoantibodies * 9-16 year old: one-time T1D and celiac autoantibodies * Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies

  • Diagnostic testDifferential Gene Expression (DGE)

    Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age

06

What researchers measure

Primary outcomes

  1. Demonstrated feasibility of large-scale population screening, as evidenced by:

    1. The percentage of parent(s) that viewed the MyChart study information who went on to complete the MyChart informed consent, HIPAA and questionnaires. 2. Of those who consented to be in the study, the percentage who went on to obtain the initial sample. 3. Of the total samples collected, percentage that were valid and results received. 4. The percentage of subjects who complete their \~60 month visit by their 6th birthday.

    Time frame: By year 10 of the study

Secondary outcomes

  1. Seroconversion rates for T1D-relevant and celiac autoantibodies

    Time frame: By year 10 of study

  2. Percentage of T1D seropositive subjects who enroll in another T1D monitoring or prevention study.

    Time frame: By year 10 of study

  3. Percentage of celiac seropositive subjects referred on to GI or primary care

    Time frame: By year 10 of study

  4. The percentage of celiac seropositive subjects who were evaluated in clinical setting

    Time frame: By year 10 of study

  5. The rate of development of overt hyperglycemia consistent with T1D (Stage 3).

    Time frame: By year 10 of study

  6. Proportion of participants developing overt hyperglycemia consistent with T1D (Stage 3), who present in diabetic ketoacidosis (DKA)

    Time frame: By year 10 of study

  7. Number and type of procedure-related adverse events

    Time frame: By year 10 of study

  8. Assessment of costs associated with implementation of study compared to potential impacts on cost and quality of life.

    Time frame: By year 10 of study

07

Study locations

4 of 4 sites recruiting
  • Sanford Bemidji Region Clinics
    Bemidji, Minnesota 56601, United States
    Recruiting
  • Sanford Bismarck Region Clinics
    Bismarck, North Dakota 58501, United States
    Recruiting
  • Sanford Fargo Region Clinics
    Fargo, North Dakota 58112, United States
    Recruiting
  • Sanford Sioux Falls Region Clinics
    Sioux Falls, South Dakota 57105, United States
    Recruiting
    • Ann Mays · Contactann.mays@sanfordhealth.org · 6053126052
    • Kurt Griffin, PhD, MD · Principal investigator
    • Sharon Hunt, BS, MS, MBA · Sub investigator
    • Candice Nelson, MD, FAAP · Sub investigator
    • Stephanie Hanson, MD, FAAP · Sub investigator
    • Louis Casas, MD, FAAP · Sub investigator
    • Brenda Thurlow, MD, FAAP · Sub investigator
    • Kyle Baum, MD · Sub investigator
    • Ann Mays, RN, CPN · Sub investigator
08

References and documents

Publications

  • Sims EK, Besser REJ, Dayan C, Geno Rasmussen C, Greenbaum C, Griffin KJ, Hagopian W, Knip M, Long AE, Martin F, Mathieu C, Rewers M, Steck AK, Wentworth JM, Rich SS, Kordonouri O, Ziegler AG, Herold KC; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022 Apr 1;71(4):610-623. doi: 10.2337/dbi20-0054. PubMed 35316839 ↗

Individual participant data

Plan to share: Yes — Deidentified patient characteristics, clinical and laboratory outcomes will be shared in an online platform.

Supporting information: Informed consent form, Clinical study report

Time frame: Data will be available no later than 12 months after the conclusion of study.

Access criteria: Data available to researchers approved by investigators.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Mar 2031, 128 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 128 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 20, 2020
StartActual
Jul 17, 2020
Primary completionEst.
Mar 2031
CompletionEst.
Mar 2031
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04477928
Lead sponsor
Sanford Health
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, Pacific Northwest Research Institute, University of Exeter
Responsible party
Sponsor
First posted
Jul 20, 2020
Start date
Jul 17, 2020
Primary completion
Mar 2031 (estimated)
Completion
Mar 2031 (estimated)
Last update
Mar 2, 2026

Study contacts

Ann Mays, RN, CPN
Contact
ann.mays@sanfordhealth.org
605-312-6052
Kurt Griffin, PhD, MD
principal investigator · Sanford Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion